| Previous close | 23.65 |
| Open | 23.78 |
| Day's range | 22.98 to 23.81 |
| 52-week range | 8.85 to 28.23 |
| Volume | 1.54M |
| Average volume (3 months) | 1.27M |
| 1-year price change | +147.95% |
| Market value | 2.39B |
| EPS (last 12 months) | -3.46 |
| Beta (1 year) | 1.43 |
| Dividend yield | None |
Company figures come from SEC filings through the quarter ending May 31, 2026. All statistics
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
For learning only, not investment advice. Chart by TradingView. How to read a stock quote.